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Andrew D. Shaw1*, Carol R. Schermer2, Dileep N. Lobo3, Sibyl H. Munson4, Victor Khangulov4,
David K Hayashida4 and John A. Kellum5After the publication of this article it has been brought
to our attention that the data in Table 3 (Table 1 in this
Erratum) and in the Additional file 3: Table S3
(Additional File 1 in this Erratum) contained mistakes as
detailed below. These mistakes have been corrected in
this Erratum.
The following values have been corrected in Table 3
(Table 1 in this Erratum):
 the entire column (far right) "Adjusted Odds Ratio
(95 % CI)"
 under Electrolyte Abnormalities, the value for "High
Mg" within the column "Saline n (%)" and the values
for "Unadjusted Odds Raio (95 % CI)" and "Adjusted
Odds Ratio (95 % CI)"
 under Electrolyte Abnormalities, ALL values for the
row labelled "Low Ca with replacement"
The single value for SOFA CV Level 2 "Saline cohort
n (%)" in Table S3 (Additional File 1 in this Erratum) has
been corrected.
In addition, we noticed that the legend for Fig. 2 (Fig. 1
in this Erratum) was incorrectly given as “Administrative
and clinical outcomes unadjusted and adjusted for Acute
Physiology Score”. The correct legend for Fig. 2 is
“Administrative and clinical outcomes unadjusted and
adjusted for APS, Elixhauser comorbidities of congestive
heart failure, hypertension and lymphoma, admission
source, census region, and payer.” The labels above the
right-hand side plots within the figure also needed correc-
tions and have been updated in this erratum.* Correspondence: andrew.shaw@vanderbilt.edu
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Table 3 Administrative and clinical outcomes by fluid cohort
Outcome/Complication Saline (n = 1558) % (n) Balanced (n = 1558) % (n) Unadjusted odds ratio (95 % CI) Adjusted odds ratio (95 % CI)
Administrative Outcomes
Cardiac 8.66 (135) 4.43 (69) 0.488 (0.362–0.659) 0.387 (0.276–0.544)
Hemorrhage 0.71 (11) 0.51 (8) 0.726 (0.291–1.809) 0.681 (0.264–1.757)
Infectious 10.14 (158) 6.03 (94) 0.569 (0.436–0.742) 0.526 (0.396–0.699)
Gastrointestinal 5.46 (85) 5.13 (80) 0.938 (0.685–1.284) 0.881 (0.636–1.220)
Neurologic 1.16 (18) 0.83 (13) 0.72 (0.352–1.474) 0.585 (0.275–1.245)
Acute renal failure 4.36 (68) 3.34 (52) 0.757 (0.524–1.093) 0.676 (0.447–1.023)
Respiratory failure 5.46 (85) 3.47 (54) 0.622 (0.439–0.882) 0.624 (0.429–0.908)
New organ failure 9.11 (142) 7.12 (111) 0.765 (0.59–0.991) 0.707 (0.506–0.986)
Clinical Outcomes
Hospital mortality 3.27 (51) 1.03 (16) 0.307 (0.174–0.54) 0.373 (0.204–0.681)
30–day readmissions 9.5 (148) 7.64 (119) 0.788 (0.612–1.014) 0.801 (0.618–1.036)
60–day readmissions 13.54 (211) 10.91 (170) 0.782 (0.63–0.97) 0.804 (0.645–1.004)
90–day readmissions 16.56 (258) 12.58 (196) 0.725 (0.593–0.886) 0.735 (0.598–0.904)
Cardiac
Dysrhythmia 10.65 (166) 6.87 (107) 0.618 (0.48–0.797) 0.632 (0.485–0.823)
Cardiac stress 6.42 (100) 2.05 (32) 0.306 (0.204–0.458) 0.289 (0.188–0.483)
Heart failure 4.04 (63) 1.48 (23) 0.356 (0.219–0.576) 0.447 (0.268–0.747)
Hemorrhage/Hematologic
Coagulopathya 11.09 (150) 7.71 (106) 0.67 (0.516–0.87) 0.602 (0.450–0.806)
Received blood transfusion 2.92 (46) 2.27 (36) 0.777 (0.5–1.209) 0.629 (0.389–1.018)
Bleeding 20.09 (313) 19.96 (311) 0.992 (0.832–1.182) 1.134 (0.942–1.365)
Infectious
Pneumonia 6.03 (94) 2.12 (33) 0.337 (0.225–0.504) 0.349 (0.226–0.539)
Sepsis 10.53 (164) 5.65 (88) 0.509 (0.389–0.666) 0.534 (0.401–0.711)
Urinary tract infection 5.91 (92) 4.69 (73) 0.783 (0.571–1.074) 0.884 (0.632–1.237)
Line infection 0.77 (12) 0 – –
Gastrointestinal
Cholecystitis 4.75 (74) 3.53 (55) 0.734 (0.514–1.048) 0.753 (0.517–1.098)
Renal
Acute Kidney Injury 5.46 (85) 4.43 (69) 0.803 (0.580–1.112) 1.052 (0.760–1.455)
Electrolyte Abnormalities
Low magnesium with replacement 4.36 (68) 2.12 (33) 0.474 (0.311–0.723) 0.565 (0.362–0.880)
High magnesium 4.43 (69) 3.4 (53) 0.760 (0.528–1.095) 0.822 (0.553–1.221)
Low potassium with replacement 14.12 (220) 7.51 (117) 0.494 (0.39–0.625) 0.510 (0.393–0.660)
High potassium 9.44 (147) 6.87 (107) 0.708 (0.546–0.918) 0.848 (0.643–1.118)
Low sodium 39.41 (614) 30.62 (477) 0.678 (0.585–0.787) 0.703 (0.602–0.821)
High sodium 7 (109) 6.03 (94) 0.854 (0.642–1.135) 0.965 (0.710–1.311)
Low calcium with replacement 1.16 (18) 0.77 (12) 0.664 (0.319–1.383) 1.125 (0.534–2.369)
Metabolic Acidosis
Lactic (pH and lactate) 0.71 (11) 0.26 (4) 0.362 (0.115–1.139) 0.397 (0.106–1.487)
Metabolic (pH and bicarbonate) 2.76 (43) 1.22 (19) 0.435 (0.252–0.75) 0.749 (0.399–1.403)
Hyperchloremic (pH and chloride) 3.47 (54) 1.22 (19) 0.344 (0.203–0.583) 0.477 (0.262–0.868)
aExcluded patients receiving warfarin
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Fig. 2 legend, edit to: Administrative and clinical outcomes unadjusted and adjusted for APS, Elixhauser comorbidities of congestive heart failure,
hypertension and lymphoma, admission source, census region, and payer
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